ITEM 8.01 OTHER EVENTS

At a special meeting of stockholders held on June 2, 2009, the stockholders of Apex Bioventures Acquisition Corporation (the "Company") voted to approve the Company's previously announced dissolution and plan of liquidation. As of the close of business on June 2, 2009, the Company's share transfer books will close and the NYSE Amex LLC will suspend trading.

Pursuant to the plan of liquidation, the Company expects to liquidate its trust account, which consists of proceeds from the Company's private placement of warrants and initial public offering and the interest accumulated thereon, including the deferred portion of the underwriters' fee held in the trust account following consummation of the public offering. Liquidating distributions from the trust account are payable upon presentation to holders of shares of common stock issued in the Company's initial public offering that hold such shares as of the close of business on June 2, 2009. The liquidating distribution is expected to be approximately $7.84 per share. No payments will be made with respect to any of the Company's outstanding warrants or shares that were acquired prior to the Company's initial public offering.

The Company has filed a certificate of dissolution with the Secretary of State of the State of Delaware for the purpose of effecting its dissolution and will be filing a Certificate of Termination of Registration on Form 15 with the Securities and Exchange Commission for the purpose of deregistering its securities under the Securities and Exchange Act of 1934, as amended. As a result, the Company will no longer be a public reporting company and its securities will cease trading on the NYSE Amex LLC.